Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE), in Collaboration with the National Organization for Rare Disorders, Inc. (NORD), the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), and the Rare Bone Disease Alliance (RBDA).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc

DATE OF RELEASE/EXPIRATION

This activity was released on August 17, 2023 and is valid until August 17, 2024. Requests for credit must be made no later than August 17, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, specialist NPs and PAs, orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, genetic counselors, and dentists.

STATEMENT OF NEED/PROGRAM OVERVIEW

Have lingering unanswered questions about fibrodysplasia ossificans progressiva (FOP), its diagnosis, and appropriate treatment? Join us for a special “FAQ Spotlight” session designed to answer frequently asked clinician questions and provide updated information on the management of FOP. Edward Hsiao, MD, PhD, will lead the session based on questions gathered during previous CME activities on FOP.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Share strategies to optimize the diagnosis and management of FOP

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 45 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must

(1) read the target audience, learning objectives, and disclosure statements,
(2) complete the educational activity online, and
(3) complete the activity evaluation.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 45 minutes. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from August 17, 2023 through August 17, 2024: 1. Review the objectives and disclosures 2. Study the educational content 3. Complete the activity evaluation

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:  

Name of Faculty or Presenter	Conflicts of Interest
Edward Hsiao, MD, PhD Professor Division of Endocrinology and Metabolism University of California, San Francisco Director, UCSF Metabolic Bone Clinic	Researcher: Ipsen Pharmaceuticals, Ultragenyx.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE), in Collaboration with the National Organization for Rare Disorders, Inc. (NORD), and the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), and the Rare Bone Disease Alliance (RBDA).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc

DATE OF RELEASE/EXPIRATION

This activity was released on April 24, 2023 and is valid until August 17, 2024. Requests for credit must be made no later than August 17, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of the primary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, and genetic counselors, and the secondary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, and specialist NPs and PAs.

STATEMENT OF NEED/PROGRAM OVERVIEW

Because fibrodysplasia ossificans progressiva, or FPOP, is exceedingly rare. even specialists such as orthopedists, endocrinologists, and rheumatologists can miss its early manifestations. The result may be missed opportunities for proper management, including avoidance of flare-up–inducing trauma. Specialists who see patients with FOP must have up-to-date knowledge regarding its cardinal signs and symptoms, diagnosis, and management.

Join a panel of clinical experts in FOP and a representative from the International FOP Association (IFOPA) to help ensure clinicians recognize FOP manifestations, make a timely diagnosis, and provide guideline-driven care. Panelists will discuss the early signs of FOP and evolving patient presentations as the disease progresses, the underlying pathophysiology and the role of activin A, and precautions that must be taken when providing routine care for FOP, including immunizations and dental care.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Recognize early hallmark signs and symptoms that may be conducive to a diagnosis of FOP
• Describe the disease course of FOP, possible triggers for flare-ups, and their impacts on patients’ and caregivers' quality of life
• Summarize the underlying pathophysiology of FOP, including its genetic causes, the role of activin, and how it affects bone formation
• Implement a management plan that includes trauma avoidance, medication, and rehabilitative and palliative care as the disease progresses
• Explain strategies to reduce risk of flare-up during routine care visits, such as visits for immunization, injection, dental work, or surgery

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Name of Faculty or Presenter	Conflicts of Interest
Edward Hsiao, MD, PhD Professor Division of Endocrinology and Metabolism University of California, San Francisco Director, UCSF Metabolic Bone Clinic	Researcher: Ipsen Pharmaceuticals, Ultragenyx.
Hope Newport, MA, CCLS Family Services Manager International FOP Association	No relevant financial relationship(s) to disclose.
Michelle Davis Executive Director International FOP Association	No relevant financial relationship(s) to disclose.
Sharon Kantanie Interview participant – Patient with FOP	No relevant financial relationship(s) to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE), in Collaboration with the National Organization for Rare Disorders, Inc. (NORD), and the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), and the Rare Bone Disease Alliance (RBDA).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc

DATE OF RELEASE/EXPIRATION

This activity was released on April 6, 2023 and is valid until August 17, 2024. Requests for credit must be made no later than August 17, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of the primary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, specialist NPs and PAs, and the secondary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, genetic counselors, and dentists.

STATEMENT OF NEED/PROGRAM OVERVIEW

Fibrodysplasia ossificans progressiva (FOP) causes abnormal bone formation in muscles and soft tissues in episodic “flare-ups” that lead to heterotopic ossification (HO), or replacement of muscle with bone. Ectopic bone formation leads inevitably to severe disability and early death. Because the disease is rare and many clinicians are unfamiliar with its presentation, diagnosis is often missed or delayed by many years. Yet early recognition is crucial to preventing trauma and avoiding medical and surgical interventions that trigger flare-ups and worsen patients’ disability and quality of life. Primary care clinicians have a crucial role in recognizing the condition early and helping patients to avoid triggers

Join a panel of expert clinicians, a patient with FOP and/or their caregiver, and a representative from the International FOP Association (IFOPA) for an interactive dialogue. Panelists will share their experiences with FOP to help clinicians better recognize its hallmark signs and symptoms, make an early and accurate diagnosis, provide appropriate referrals, and offer the most current standard of care.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Recognize early hallmark signs and symptoms that may be conducive to a diagnosis of FOP
• Develop strategies to work with patients and caregivers to reduce risk of trauma and recognize flare ups early to initiate the recommended management plan
• Describe the impacts of FOP on patients’ and caregivers’ quality of life over the disease course

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Name of Faculty or Presenter	Conflicts of Interest
Edward Hsiao, MD, PhD Professor Division of Endocrinology and Metabolism University of California, San Francisco Director, UCSF Metabolic Bone Clinic	Researcher: Ipsen Pharmaceuticals, Ultragenyx.
Hope Newport, MA, CCLS Family Services Manager International FOP Association	No relevant financial relationship(s) to disclose.
Michelle Davis Executive Director, International FOP Association	To be disclosed prior to presentation.
Lisa Gillooly Parent of a child with Fibrodysplasia Ossificans Progressiva	No relevant financial relationship(s) to disclose.
Sharon Kantanie Interview participant – Patient with FOP	No relevant financial relationship(s) to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.